Scientists test gentler prep for blood cancer transplants
NCT ID NCT07214064
Summary
This study is testing the safety of adding a drug called venetoclax to a standard, lower-intensity chemotherapy regimen given before a stem cell transplant. The goal is to see if this combination can better control acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) without causing more severe side effects in this vulnerable group. The trial will enroll 27 adults whose disease is under control and who are eligible for a transplant from a matched donor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital , Department of Internal Medicine II
Tübingen, Baden-Wurttemberg, 72076, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.